Taysha Gene Therapies Completes Pivotal Trial Dosing for TSHA-102, Reports Strong Longer-Term Rett Syndrome Data
TSHA has more than doubled off its 52-week low of $2.25 on elevated volume (2.3× avg).
Summary
Taysha Gene Therapies announced the completion of dosing in its pivotal REVEAL trial for TSHA-102 in Rett syndrome, alongside positive longer-term clinical data from Part A, showing durable functional gains and a clear path to BLA submission.
Key Events · Product Development and Regulatory · TSHA
-
Pivotal Trial Dosing Completed
Taysha completed dosing 17 patients in the REVEAL pivotal trial for TSHA-102 in Rett syndrome, a major step towards regulatory submission.
-
Strong Longer-Term Clinical Data Reported
Part A of the REVEAL Phase 1/2 trials showed 100% of patients (N=12) gained or regained at least one developmental milestone by 12 months, with durable and deepening functional gains (310 total gains) and no treatment-related serious adverse events.
-
Clear Regulatory Pathway Outlined
The company expects topline data from the 6-month interim analysis and FDA feedback on the BLA submission pathway in the first half of 2027, with FDA alignment on the registrational strategy.
-
ASPIRE Trial Progressing
The ASPIRE safety-focused trial for younger patients (2 to <4 years) is ongoing and overenrolled to 4 patients, with dosing expected to complete in July 2026. Safety data from this trial will support a broad label.
Analysis · TSHA · Life Sciences
This filing provides a highly positive update on Taysha's lead gene therapy candidate, TSHA-102, for Rett syndrome. The completion of dosing in the pivotal REVEAL trial is a major de-risking event, moving the program closer to regulatory submission. The reported longer-term data from Part A, demonstrating a 100% response rate, durable and deepening functional gains across multiple domains, and a favorable safety profile, significantly strengthens the drug's profile. The company's outlined timeline for FDA feedback and BLA submission in 1H 2027, coupled with FDA alignment on the registrational strategy, provides a clear path forward and could substantially increase investor confidence in the drug's commercial potential.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 41.9% of the 327 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.46%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, TSHA was trading at $6.68 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.8B. The 52-week trading range was $2.25 to $7.30. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.